Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
; : 22-30, 2016.
Article
in En
| WPRIM
| ID: wpr-83858
Responsible library:
WPRO
ABSTRACT
BACKGROUND: The purpose of this study was to document outcomes following withdrawal of a single inhaler (step-down) in chronic obstructive pulmonary disease (COPD) patients on triple therapy (long-acting muscarinic antagonist and a combination of long-acting beta2-agonists and inhaled corticosteroid), which a common treatment strategy in clinical practice. METHODS: Through a retrospective observational study, COPD patients receiving triple therapy over 2 years (triple group; n=109) were compared with those who had undergone triple therapy for at least 1 year and subsequently, over 9 months, initiated inhaler withdrawal (step-down group, n=39). The index time was defined as the time of withdrawal in the stepdown group and as 1 year after the start of triple therapy in the triple group. RESULTS: Lung function at the index time was superior and the previous exacerbation frequency was lower in the stepdown group than in the triple group. Step-down resulted in aggravating disease symptoms, a reduced overall quality of life, decreasing exercise performance, and accelerated forced expiratory volume in 1 second (FEV1) decline (54.7+/-15.7 mL/yr vs. 10.7+/-7.1 mL/yr, p=0.007), but there was no observed increase in the frequency of exacerbations. CONCLUSION: Withdrawal of a single inhaler during triple therapy in COPD patients should be conducted with caution as it may impair the exercise capacity and quality of life while accelerating FEV1 decline.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Quality of Life
/
Nebulizers and Vaporizers
/
Forced Expiratory Volume
/
Retrospective Studies
/
Pulmonary Disease, Chronic Obstructive
/
Observational Study
/
Lung
/
Lung Diseases
Type of study:
Observational_studies
Limits:
Humans
Language:
En
Journal:
Tuberculosis and Respiratory Diseases
Year:
2016
Type:
Article